Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression

Hepatology

Volumn 52, Issue 1, 2010, Pages 197-203

  Sinakos, Emmanouil ^a   Marschall, Hanns Ulrich ^b   Kowdley, Kris V ^c   Befeler, Alex ^d   Keach, Jill ^a   Lindor, Keith ^a  

^a MAYO CLINIC   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; LITHOCHOLIC ACID; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILE ACID BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VARICOSIS;

ADOLESCENT; ADULT; AGED; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LITHOCHOLIC ACID; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 77954231348     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23631     Document Type: Article

References (30)

1. Silveira M, Lindor K. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol 2008;14:3338-3349.
2. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
3. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792-800.
4. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-1562. (Pubitemid 32455090)
5. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907. (Pubitemid 32959399)
6. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.
7. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. HEPATOLOGY 2009;50:808-814.
8. Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, et al. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. HEPATOLOGY 1989;10:414-419. (Pubitemid 19256549)
9. Crosignani A, Podda M, Battezzati PM, Bertolini E, Zuin M, Watson D, et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. HEPATOLOGY 1991;14:1000-1007.
10. Fedorowski T, Salen G, Tint GS, Mosbach E. Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology 1979;77:1068-1073.
11. Benedetti A, Alvaro D, Bassotti C, Gigliozzi A, Ferretti G, La Rosa T, et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. HEPATOLOGY 1997;26:9-21. (Pubitemid 27280301)
12. Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 2006;168:410-422. (Pubitemid 43271140)
13. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. HEPATOLOGY 2004;40:693-698. (Pubitemid 39265592)
14. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005;129:476-485.
15. Marschall HU, Griffiths WJ, Götze U, Zhang J, Wietholtz H, Busch N, et al. The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine. HEPATOLOGY 1994;20:845-853. (Pubitemid 24296490)
16. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001;35:134-146.
17. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II. Dig Dis Sci 1982;27:833-856. (Pubitemid 12053375)
18. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part I. Dig Dis Sci 1982;27:737-761.
19. Poupon RE, Chrétien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. HEPATOLOGY 1993;17:599-604. (Pubitemid 23115504)
20. Combes B, Carithers RL, Maddrey WC, Munoz S, Garcia-Tsao G, Bonner GF, et al. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. HEPATOLOGY 1999;29:1649-1654. (Pubitemid 29247034)
21. Lindor KD, Lacerda MA, Jorgensen RA, DeSotel CK, Batta AK, Salen G, et al. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. Am J Gastroenterol 1998;93:1498-1504.
22. van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP, Salemans JM, Tangerman A, van Buuren HR, et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. J Hepatol 1996;25:887-894.
23. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl 1994;204:1-15.
24. Rudolph G, Kloeters-Plachky P, Sauer P, Stiehl A. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate. Eur J Clin Invest 2002;32:575-580.
25. Sauer P, Benz C, Rudolph G, Kloeters-Plachky P, Stremmel W, Stiehl A, et al. Influence of cholestasis on absorption of ursodeoxycholic acid. Dig Dis Sci 1999;44:817-822.
26. Walker S, Rudolph G, Raedsch R, Stiehl A. Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 1992;102:810-815.
27. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. Dig Dis Sci 2006;51:618-622.
28. Trauner M, Fickert P, Halilbasic E, Moustafa T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 2008;158:542-548.
29. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lambert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123:1238-1251.
30. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:2790-2799.